1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 2: 

MR imaging contrast
MR Imaging Contrast AgentExamplesPredominant EffectMR Imaging SensitivityNotes
T1 agentGd-DTPA (magnevist), Gd-DOTA (dotarem), Mn2+ T1++Gd is chelated for toxicity reasons
T2 agentSPIO, USPIO, MION, CLIOT2++++Large range of sizes
CEST, PARACESTAmino acids, sugars; Eu-DOTASaturation transfer++Preclinical stage
Heteronuclei19F, 31PHot spot imaging+Negligible background signal
  • 

    Note:—Plus signs indicate the relative sensitivity of the different contrast mechanisms.